Back to results
US 2023/0068663 A1Published application
Novel lilrb2 antibodies and uses thereof
AssigneesBoard of Regents, The University of Texas System, Immune-Onc Therapeutics, Inc.
InventorsZhiqiang AN, Ningyan ZHANG, Zhiqiang KU, Chengcheng ZHANG, Xiaoye XU, Heyu CHEN, JingJing XIE, Maria Jose COSTA, An SONG, X. Charlene LIAO
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
Claims59
An isolated monoclonal antibody or an antigen-binding fragment thereof comprising a heavy chain (HC) variable region (VH) and a light chain (LC) variable region (VL) comprising clone-paired CDR sequences as set forth in Table 2;
- and variants thereof wherein one or more of the HC-CDRs and/or LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof.
A monoclonal antibody that binds to LILRB2 and:
- (a) does not bind to LILRA or another LILRB;
- or
- (b) binds to LILRB2 Domain 1 or 4;
- or
- (c) activates or antagonizes LILRB2;
- or
- (d) enhances monocyte inflammatory potential;
- or
- (e) enhances T cell activation;
- or
- (f) modulates M2a macrophage phenotype;
- or
- (g) prevents myeloid-derived suppressor cell function;
- or
- (h) inhibits leukemia cell migration and/or infiltration in vivo.
12 more elements
Dependencies are inferred from the claim text.